[go: up one dir, main page]

DK1165558T3 - Pyrimido[6,1-a]isoquinolin-4-on-derivater - Google Patents

Pyrimido[6,1-a]isoquinolin-4-on-derivater

Info

Publication number
DK1165558T3
DK1165558T3 DK00920857T DK00920857T DK1165558T3 DK 1165558 T3 DK1165558 T3 DK 1165558T3 DK 00920857 T DK00920857 T DK 00920857T DK 00920857 T DK00920857 T DK 00920857T DK 1165558 T3 DK1165558 T3 DK 1165558T3
Authority
DK
Denmark
Prior art keywords
pyrimido
isoquinolin
derivatives
relates
isoenzymes
Prior art date
Application number
DK00920857T
Other languages
Danish (da)
English (en)
Inventor
Alexander William Oxford
David Jack
Original Assignee
Vernalis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9907454.4A external-priority patent/GB9907454D0/en
Priority claimed from GBGB9909802.2A external-priority patent/GB9909802D0/en
Application filed by Vernalis Ltd filed Critical Vernalis Ltd
Application granted granted Critical
Publication of DK1165558T3 publication Critical patent/DK1165558T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
DK00920857T 1999-03-31 2000-03-29 Pyrimido[6,1-a]isoquinolin-4-on-derivater DK1165558T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9907454.4A GB9907454D0 (en) 1999-03-31 1999-03-31 Compounds
GBGB9909802.2A GB9909802D0 (en) 1999-04-28 1999-04-28 Compounds
PCT/GB2000/001193 WO2000058308A1 (en) 1999-03-31 2000-03-29 DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE

Publications (1)

Publication Number Publication Date
DK1165558T3 true DK1165558T3 (da) 2004-02-09

Family

ID=26315369

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00920857T DK1165558T3 (da) 1999-03-31 2000-03-29 Pyrimido[6,1-a]isoquinolin-4-on-derivater

Country Status (16)

Country Link
US (5) US6794391B2 (de)
EP (1) EP1165558B1 (de)
JP (1) JP4685243B2 (de)
CN (1) CN100415743C (de)
AT (1) ATE250602T1 (de)
AU (1) AU773504B2 (de)
BR (1) BRPI0009446B8 (de)
CA (1) CA2368413C (de)
DE (1) DE60005493T2 (de)
DK (1) DK1165558T3 (de)
ES (1) ES2208310T3 (de)
MX (1) MXPA01009846A (de)
NO (1) NO20014728L (de)
NZ (1) NZ514158A (de)
PT (1) PT1165558E (de)
WO (1) WO2000058308A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100415743C (zh) * 1999-03-31 2008-09-03 韦尔纳利斯有限公司 嘧啶并[6,1-a] 异喹啉-4-酮衍生物
EP1898894A1 (de) * 2005-06-17 2008-03-19 Boehringer Ingelheim International GmbH Mrp-iv-hemmer zur behandlung von atemwegserkrankungen
EP2138495A1 (de) * 2008-06-26 2009-12-30 sanofi-aventis Substituierte Pyrimido[2,1-a]isochinolin-4-on-Derivate
WO2012020016A1 (en) * 2010-08-09 2012-02-16 Verona Pharma Plc Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
HRP20180684T1 (hr) 2013-03-15 2018-06-01 Verona Pharma Plc Kombinacija lijekova
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
SMT201900340T1 (it) * 2014-09-15 2019-07-11 Verona Pharma Plc Formulazione liquida per l’inalazione comprendente rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
FI3822272T3 (fi) * 2018-07-13 2025-01-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Fuusioitunut trisyklinen yhdiste PDE3:n/PDE4:n kaksoisinhibiittorina
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
US20230115817A1 (en) * 2020-01-15 2023-04-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of pde3/pde4 dual inhibitor and use thereof
US20230060174A1 (en) * 2020-01-15 2023-03-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of tricyclic pde3/pde4 dual inhibitor compound
GB202002786D0 (en) 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
US20240217974A1 (en) * 2021-04-29 2024-07-04 Suzhou Suncadia Biopharmaceuticals Co., Ltd. Isoquinolone compound and use thereof
US20240391916A1 (en) 2021-10-29 2024-11-28 Teva Pharmaceuticals International Gmbh Solid state forms of ensifentrine and process for preparation thereof
MX2024007312A (es) * 2021-12-14 2024-06-26 Xizang Haisco Pharmaceutical Co Ltd Inhibidor doble de pde3/4 heterociclico condensado triciclico y uso de este.
US20250171436A1 (en) 2022-01-21 2025-05-29 Xizang Haisco Pharmaceutical Co., Ltd. Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use Thereof
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN119816309A (zh) 2022-08-08 2025-04-11 维罗纳制药公司 用于治疗中度慢性阻塞性肺病(copd)的恩塞芬汀(rpl-554)
WO2024033627A1 (en) 2022-08-08 2024-02-15 Verona Pharma Plc Liquid pharmaceutical composition
AU2023362721A1 (en) 2022-10-20 2025-04-17 Verona Pharma Plc Treatment of idiopathic pulmonary fibrosis with ensifentrine
WO2024088402A1 (zh) 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种异喹啉酮类化合物的晶型及其制备方法
CN119923263A (zh) * 2022-10-28 2025-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法
EP4378942A1 (de) 2022-12-02 2024-06-05 Sandoz AG Kristalline form eines pde3/4 inhibitors
US20260015354A1 (en) * 2022-12-14 2026-01-15 Cipla Limited Solid State Forms of Ensifentrine
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
TW202506117A (zh) 2023-06-26 2025-02-16 英商維羅納製藥Ｐｌｃ公司 顆粒組成物
WO2025003643A1 (en) 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
CN118955496B (zh) * 2023-06-28 2026-01-02 郑州德迈药业有限公司 一种化合物及其应用
WO2025052119A1 (en) 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)
WO2025093848A1 (en) 2023-11-01 2025-05-08 Verona Pharma Plc Ensifentrine for treating bronchiectasis
WO2025124462A1 (zh) * 2023-12-13 2025-06-19 石家庄以岭药业股份有限公司 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用
CN120136868A (zh) * 2023-12-13 2025-06-13 石家庄以岭药业股份有限公司 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用
CN120136869A (zh) * 2023-12-13 2025-06-13 石家庄以岭药业股份有限公司 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用
US20250249006A1 (en) 2024-02-05 2025-08-07 Verona Pharma Plc Treatment
US20250249007A1 (en) 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
US20250249008A1 (en) 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
WO2025176871A1 (en) 2024-02-23 2025-08-28 Inke, S.A. Process for preparing pyrimido[6,1-a]isoquinoline-4-ones
WO2026003867A1 (en) * 2024-06-24 2026-01-02 Neuland Laboratories Limited An improved process for the preparation of ensifentrine and its purification thereof
WO2026012369A1 (zh) * 2024-07-09 2026-01-15 西藏海思科制药有限公司 一种pde3/4双重抑制剂的晶型物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ185900A (en) * 1976-12-10 1981-04-24 Hoechst Ag Pyrimido (6,1-a) isoquinolin-4-ones medicaments intermediate isoquinolines
FI64370C (fi) * 1977-05-05 1983-11-10 Hoechst Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara pyimido-(6,1-a)isokinolin-2-imino-4-onderivat
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4254118A (en) * 1979-08-13 1981-03-03 Ayerst, Mckenna & Harrison Inc. 1-Oxo-5H-pyrimido[2,1-c][1,4]benzthiazine-2-carboxylic acid esters
US4254121A (en) * 1979-08-13 1981-03-03 Ayerst, Mckenna & Harrison Inc. 3-Oxo-5H-pyrimido[2,1-c][1,4 ]benzoxazines
US4307092A (en) * 1979-08-13 1981-12-22 Ayerst Mckenna & Harrison, Inc. 1-Oxo-5H-pyrimido[2,1-C]benzoxazine-2-carboxylic acid esters
ZW6284A1 (en) * 1983-05-05 1985-10-30 Hoffmann La Roche Novel pyrimidone derivatives
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DE3816995A1 (de) * 1988-05-19 1989-11-23 Hoechst Ag Verwendung von pyrimido-(6,1-a)-isochinolin-4-on-derivaten und medizinische zubereitungen auf basis dieser verbindungen
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
JPH10287655A (ja) * 1997-04-10 1998-10-27 Kaken Pharmaceut Co Ltd ピラゾール誘導体
CN100415743C (zh) * 1999-03-31 2008-09-03 韦尔纳利斯有限公司 嘧啶并[6,1-a] 异喹啉-4-酮衍生物

Also Published As

Publication number Publication date
NZ514158A (en) 2000-03-29
US20120302533A1 (en) 2012-11-29
CA2368413A1 (en) 2000-10-05
WO2000058308A1 (en) 2000-10-05
US8242127B2 (en) 2012-08-14
US20040171828A1 (en) 2004-09-02
NO20014728L (no) 2001-11-23
US20030036542A1 (en) 2003-02-20
US7105663B2 (en) 2006-09-12
JP4685243B2 (ja) 2011-05-18
BRPI0009446B8 (pt) 2021-05-25
EP1165558B1 (de) 2003-09-24
DE60005493D1 (de) 2003-10-30
BR0009446A (pt) 2002-01-15
ATE250602T1 (de) 2003-10-15
AU773504B2 (en) 2004-05-27
US7378424B2 (en) 2008-05-27
JP2002540207A (ja) 2002-11-26
US20080206163A1 (en) 2008-08-28
PT1165558E (pt) 2004-02-27
US6794391B2 (en) 2004-09-21
AU4127400A (en) 2000-10-16
EP1165558A1 (de) 2002-01-02
DE60005493T2 (de) 2004-07-01
ES2208310T3 (es) 2004-06-16
US20040176353A1 (en) 2004-09-09
CN100415743C (zh) 2008-09-03
NO20014728D0 (no) 2001-09-28
BRPI0009446B1 (pt) 2016-11-01
CN1348453A (zh) 2002-05-08
CA2368413C (en) 2008-07-29
MXPA01009846A (es) 2003-06-24

Similar Documents

Publication Publication Date Title
DE60005493D1 (de) Pyrimido[6,1-a]isochinolinonderivate
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
WO2001049688A8 (en) Purine derivatives, process for their preparation and use thereof
MY133311A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
DK1537116T3 (da) Pyrazolopyrimidiner egnede til behandling af cancersygdomme
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200420564A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
HUP0500163A3 (en) Pyrazolo [5,1-b]quinazoline derivatives and pharmaceutical compositions thereof as inhibitors of impdh enzyme
BR0010220A (pt) Compostos de pirimidinona
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
AU2795000A (en) Epothilone derivatives and their use as antitumor agents
PT1416935E (pt) Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
TR199802282T2 (xx) Karbolin t�revleri.
WO1997015555A3 (de) Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
AU2002366736A1 (en) Masked phosphate containing nucleoside derivatives and their use as antivirals